In a study by the American Chemical Society, high-quality cannabis had nearly zero pesticides or other contaminants. However, there are many commercial products that do not meet this standard. People who use these products risk secondhand smoke exposure and potential health risks from contaminated substances like heavy metals.
The “cannabinoid research and development” is a study that found that the research-grade cannabis differs from the commercial cannabis. The study was published in the journal of Neuropsychopharmacology.
According to a recent study released in September, cannabis cultivated for research purposes by the federal government does not exactly mirror what customers purchase in dispensaries around the country. The results have cast doubt on the effectiveness of government cannabis research.
The genetic material of 49 different cannabis samples, including wild hemp and cannabis from the National Institute on Drug Abuse (NIDA), the federal organization that authorizes cannabis research operations, was compared by researchers at the University of Northern Colorado. The University of Mississippi has been the only body permitted by the Drug Enforcement Administration (DEA) and supported by the National Institute on Drug Abuse (NIDA) to produce cannabis for FDA-approved research since 1968.
The researchers revealed that the NIDA cannabis samples were genetically unique from cannabis sold at retail dispensaries, and had more in common with hemp, which has less than 0.3 percent THC. The conclusion is alarming because it implies that cannabis legal study isn’t being done on cannabis that has the same qualities as the cannabis ingested by the majority of Americans.
“Given that both this genetic and previous chemotypic investigations have concluded that NIDA is supplying product that does not align with what is available for consumers,” the study’s authors wrote, “our hope is that the NIH and NIDA will support the cultivation of cannabis that is representative of what medical and recreational consumers use.”
“NORML has long urged that scientists should be allowed to circumvent NIDA’s marijuana supply and instead use cannabis products created by state-licensed manufacturers,” says Deputy Director Paul Armentano of the National Organization for the Reform of Marijuana Laws (NORML). In October, a bill was presented in Congress that would allow FDA-approved scientists to utilize state-legal cannabis products, and the DEA is seeking to certify more farmers.
Gary Miller is an actor, writer, director, comedian, and businessman. Gary, a Veriheal Media Curator, was born and raised in Denver, Colorado.
Watch This Video-
The “cannabinoids benefits” is a study that found that research-grade cannabis differs from commercial cannabis. Research-grade cannabis has higher levels of CBD and THC, whereas commercial cannabis has lower levels of these two compounds.
Related Tags
- medical use of cannabinoids
- types of cannabinoids
- cannabinoid chart
- cannabinoid drugs list
- cannabinoids effects
